bms754807
Small moleculeexperimental
Clinical trial activity
7 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2008 (NCT00569036)
Timeline
Indications
Mechanism of action
IGF1R inhibitor
- Insulin receptorINHIBITOR
INSR inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
C[C@@]1(C(=O)Nc2ccc(F)nc2)CCCN1c1nc(Nc2cc(C3CC3)n[nH]2)c2cccn2n1- Mol. weight
- 461.51 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL575448 ↗
Also known as
- bms754807
- bms 754807
- bms-754807
- bms-754807
- bms-754807
- bms-754807
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01525823 | Phase 1 | Feb 1, 2012 | Bristol-Myers Squibb |
| NCT01225172 | Phase 2 | Dec 1, 2010 | Bristol-Myers Squibb, Mayo Clinic |
| NCT00908024 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2009 | Bristol-Myers Squibb |
| NCT00898716 | Phase 1 | Sep 1, 2009 | Bristol-Myers Squibb |
| NCT00788333 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2009 | Bristol-Myers Squibb |
| NCT00793897 | Phase 1 | Apr 1, 2009 | Bristol-Myers Squibb |
| NCT00569036 | Phase 1 | Apr 1, 2008 | Bristol-Myers Squibb |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 7 | 7 | 2 | 2008 |
| Mayo Clinic | Academic/Hospital | 1 | 0 | 1 | 2010 |
2 organizations
Page 1 / 1